AMENDMENT TO TRANSITIONAL SERVICES AND SEPARATION AGREEMENTTransitional Services and Separation Agreement • April 1st, 2021 • Aerpio Pharmaceuticals, Inc. • Pharmaceutical preparations • Ohio
This Amendment to Transitional Services and Separation Agreement (this “Amendment”) is made as of April 1, 2021 (the “Amendment Effective Date”), by and between Kevin G. Peters, MD (“Executive”) and Aerpio Pharmaceuticals, Inc., a Delaware corporation (the “Company”, and together with Executive, each, a “Party”, and collectively, the “Parties”). Capitalized terms used and not otherwise defined herein shall have the meanings ascribed to such terms in the Transitional Services and Separation Agreement (as defined below).
CONSULTING SERVICES AGREEMENTConsulting Services Agreement • April 1st, 2021 • Aerpio Pharmaceuticals, Inc. • Pharmaceutical preparations • Ohio
This Consulting Services Agreement (this “Agreement”) is made as of April 1, 2021 (the “Effective Date”), by and between Kevin G. Peters, MD (“Consultant”), and Aerpio Pharmaceuticals, Inc., a Delaware corporation with a principal place of business at 9987 Carver Road, Suite 420, Cincinnati, Ohio 45242 (“Aerpio” or the “Company”), each individually a “Party” and collectively “the Parties”. Notwithstanding anything to the contrary herein, this Agreement shall be void ab initio if Consultant fails to comply with the Transitional Services and Separation Agreement dated February 9, 2021 between Consultant and the Company (the “Transitional Services and Separation Agreement”) prior to the Effective Date, as determined by the Company in its sole discretion. Capitalized terms used herein and not otherwise defined shall have the meanings ascribed to such terms in the Transitional Services and Separation Agreement.
